Da Volterra
Biotechnology Awards - 2020
Best Microbiome Innovations Company 2020
Most Pioneering Microbiota Protection Product: DAV132
Da Volterra is a clinical stage biotech company located in Paris, France, and developing novel microbiota-protective therapies.
Da Volterra’s lead product, DAV132, is a Phase 3-ready first-in-class colon-targeted adsorbent developed in several indications associated to the preservation of a healthy microbiota in patients under antibiotic treatments.
This includes the prevention of C. difficile infection (CDI) and resistant bacteria colonization in patients who previously suffered from CDI and in immuno-compromised patients, prevention of Graft-vs-Host Disease in patients with hematologic malignancies, as well as preservation of Immune Checkpoint Inhibitors’ efficacy in cancer patients receiving antibiotics.
Website: https://davolterra.com/
Contact:
[email protected]